The global dermatology excimer laser market size was valued at USD 636.07 million in 2025 and is projected to grow from USD 701.84 million in 2026 to USD 1542.06 million by 2034, registering a CAGR of 10.34% during the forecast period from 2026 to 2034. North America dominated the dermatology excimer laser market with a market share of 38.4% in 2025.
Dermatology excimer lasers are medical laser systems that produce concentrated ultraviolet light for treating certain skin conditions. They typically deliver a focused beam to targeted areas of the skin, allowing treatment while minimizing exposure to surrounding healthy tissue. Excimer laser therapy is commonly used in dermatology for conditions such as psoriasis, vitiligo, and other localized skin disorders where controlled ultraviolet treatment may be appropriate. The treatment works by delivering a specific wavelength of light to the affected skin, with the dose adjusted according to the condition and the patient's response. Dermatology excimer lasers are generally used by trained healthcare professionals in clinical settings, with treatment parameters carefully controlled to reduce the risk of skin irritation or excessive UV exposure.
Download a Free Sample To learn more about this report,
Excimer Lamps Are Creating Competition Within Targeted Phototherapy
Demand for targeted phototherapy is encouraging the use of 308 nm excimer lamps alongside conventional excimer lasers, particularly where clinics seek alternative device formats. A systematic review of six studies covering 411 patients and 764 lesions found no significant difference in ≥50% or ≥75% repigmentation between excimer lamps and excimer lasers for vitiligo. This comparable clinical performance is broadening device choices within targeted phototherapy.
Portable and Handheld Delivery Is Expanding Targeted Treatment Models
The dermatology excimer laser market analysis shows that demand for localized treatment is supporting smaller and more focused phototherapy devices that can target individual lesions without exposing unaffected skin. Recent clinical research comparing 308 nm LED and excimer lamp treatment included 174 patients and 269 vitiligo patches, showing similar efficacy after 16 sessions, which indicates increasing interest in compact targeted light-delivery technologies. This shift can expand targeted phototherapy into more flexible treatment settings and support treatment of localized lesions.
Adoption of Excimer Laser Treatment in Specialty Clinics and Rising Preference for Non-Invasive Dermatological Treatments Drive Market
Greater adoption of excimer laser treatment in specialty clinics increases demand for dermatology excimer laser systems as more providers add targeted phototherapy to their treatment offerings. Dermatology clinics, for example, can use excimer lasers for localized psoriasis and vitiligo lesions where focused treatment is required. This wider clinical adoption encourages equipment procurement and supports demand for excimer laser systems.
Rising preference for non-invasive dermatological treatments increases demand for excimer laser therapy as patients and clinicians seek localized treatment options without surgical intervention. Patients with localized vitiligo or psoriasis, for example, can receive targeted laser treatment while limiting exposure to unaffected skin. This preference expands the patient base for non-invasive phototherapy and supports demand for dermatology excimer laser equipment.
Shortage of Skilled Dermatologists and Laser Specialists and Risk of Skin Irritation and Treatment-Related Adverse Effects Restrain Market Expansion
Shortage of skilled dermatologists and laser specialists can limit the availability of professionals capable of operating excimer laser systems and selecting appropriate treatment protocols. Limited specialist availability can restrict treatment capacity, particularly in areas with fewer advanced dermatology facilities. Consequently, workforce shortages can slow adoption and constrain market expansion.
Risk of skin irritation and treatment-related adverse effects can create concerns among patients undergoing excimer laser therapy, particularly when treatment intensity or exposure is not appropriately managed. These concerns can reduce patient acceptance and encourage healthcare providers to use alternative treatment options in some cases. As a result, safety concerns can slow treatment adoption and limit market growth.
Dermatology Excimer Lasers for Pediatric Skin Disorders and Dermatology Excimer Lasers for Scalp and Hair-Related Conditions Offers Growth Opportunities
Pediatric dermatology clinics and specialized healthcare providers are key customers for excimer laser solutions designed for localized skin disorders in children. Companies such as XTRAC can expand revenue through pediatric treatment platforms, specialized clinical protocols, and equipment supply agreements with dermatology centers.
Dermatology clinics, hair restoration centers, and patients with localized scalp conditions are key customers for excimer laser applications targeting selected inflammatory and pigment-related scalp disorders. Companies such as Alma Lasers can generate revenue through specialized laser platforms, treatment accessories, and partnerships with dermatology and aesthetic clinics, contributing to dermatology excimer laser market growth.
High Cost of Excimer Laser Equipment and Maintenance and Competition from Alternative Phototherapy and Topical Treatments Hinder Growth
Excimer laser systems require substantial capital investment along with specialized maintenance, calibration, and replacement components, increasing the financial burden for dermatology clinics. These costs can make adoption difficult for smaller practices and limit the expansion of excimer laser treatment capacity beyond well-funded hospitals and specialty centers.
Dermatologists can choose among narrowband UVB, topical therapies, systemic medicines, and other phototherapy approaches depending on the condition and patient profile. The availability of these alternatives can reduce demand for excimer laser treatments and make it more difficult for equipment manufacturers to expand adoption across diverse dermatology settings.
The table top excimer lasers segment accounted for a market share of 46.8% in 2025 due to their suitability for dermatology clinics and hospitals requiring reliable, high-performance laser systems for targeted phototherapy. Their stable operation, precise treatment delivery, and ability to support repeated procedures contribute to the segment’s dominant market position.
The hand-held excimer lasers segment is expected to grow at a CAGR of 10.26% during the forecast period 2026-2034, driven by their compact design, portability, and ability to deliver targeted phototherapy to localized skin lesions. Flexible handling and suitability for outpatient and point-of-care dermatological procedures support adoption of hand-held excimer laser systems. The trolley-mounted excimer lasers segment provides mobility within clinical settings while retaining the functionality of larger excimer laser systems. Their suitability for dermatology departments requiring flexible positioning and targeted treatment delivery supports continued use across clinical applications.
Request Customizationto receive a tailored report.
The alopecia areata segment is expected to grow at a CAGR of 10.34% during the forecast period 2026-2034, driven by the use of excimer laser therapy for targeted treatment of localized hair loss and stimulation of affected areas. The ability to deliver focused ultraviolet light to specific lesions supports the use of excimer lasers as a localized treatment option for alopecia areata.
The psoriasis segment accounted for a market share of 32.6% in 2025 due to the established use of excimer laser therapy for targeted treatment of localized psoriatic lesions. Precise delivery of ultraviolet light to affected skin areas supports treatment while limiting exposure to surrounding healthy tissue, contributing to the segment’s dominant market position. The vitiligo segment uses excimer laser therapy to deliver targeted ultraviolet light to depigmented skin areas and support repigmentation. Its suitability for localized lesions and controlled treatment delivery supports continued adoption in dermatological practice.
The atopic dermatitis segment uses excimer laser therapy for targeted phototherapy in selected patients with localized inflammatory skin lesions. Controlled ultraviolet light delivery supports localized treatment approaches where conventional topical therapies may provide limited results. The allergic rhinitis segment applies excimer laser-based phototherapy approaches to target inflammatory responses associated with nasal symptoms. Interest in localized, non-systemic treatment approaches supports continued exploration and clinical use of excimer laser technologies for allergic rhinitis.
Speak to an Analystto discuss market opportunities.
The North America dermatology excimer laser market accounted for the largest regional share of 38.4% in 2025, supported by a large addressable patient population and expanding treatment coverage, with updated U.S. reimbursement codes scheduled to take effect in 2027, expanding excimer-laser eligibility to inflammatory and autoimmune skin conditions beyond psoriasis, while the National Psoriasis Foundation reports that more than 8 million Americans currently live with psoriasis, supporting demand for targeted phototherapy.
The US dermatology excimer laser market will be supported by continued demand for targeted phototherapy, with Medicare phototherapy utilization showing continued relevance in recent evidence and CMS maintaining national coverage for phototherapy in psoriasis, while a 2026 clinical review identifies excimer laser therapy among established phototherapy modalities, supporting ongoing use of light-based dermatological treatments. The Canada dermatology excimer laser market will be supported by continued investment in dermatological care, with Health Canada allocating more than C$421 million in planned 2026-27 spending to improve affordable access to drugs and devices, with evaluation continuing through 2030-31, while Canada’s 2026-27 health plan prioritizes improving healthcare accessibility and affordability, supporting demand for advanced dermatology treatment technologies.
Unlock Regional Insightsto access country-level data, & regional trends.
The Asia Pacific dermatology excimer laser market is expected to grow at a CAGR of 10.68% during 2026-2034, supported by expanding access to advanced dermatological care, with the WHO’s South-East Asia regional strategy targeting universal health coverage by 2030 and stronger access to quality health services, creating opportunities for wider adoption of targeted phototherapy technologies.
The China dermatology excimer laser market will be supported by broader healthcare access, with China targeting an average life expectancy of 80 years by 2030 and a stronger primary-care network, including a 15-minute primary healthcare service circle, supporting wider access to dermatological treatment technologies. The Japan dermatology excimer laser market will be supported by continued healthcare-system modernization, with Japan’s government targeting ¥150 trillion in GX investment over the next 10 years, including healthcare and life-science innovation, supporting investment in advanced medical technologies and treatment equipment.
The India dermatology excimer laser market will be supported by healthcare infrastructure and medical-technology investment, with the 2026-27 health budget allocating ₹1,06,530.42 crore and ₹4,821.21 crore for the Department of Health Research, supporting expansion of healthcare infrastructure, medical research, and technology adoption. The South Korea dermatology excimer laser market will be supported by healthcare technology investment, with the government planning 30 national healthcare technologies and setting the direction for 2027 healthcare R&D investment, while its 2026-2030 advanced regenerative-medicine plan targets at least 150 approved clinical research or treatment plans by 2030, supporting broader adoption of advanced medical technologies.
The Europe dermatology excimer laser market accounted for a regional share of 27.6% in 2025, supported by continued investment in healthcare innovation, with the EU allocating €42.7 billion to healthcare measures through the Recovery and Resilience Facility as of 2026 and targeting stronger adoption of innovative health technologies, while EU health research programs continue to support new technologies and therapies, creating opportunities for advanced phototherapy equipment.
The Germany dermatology excimer laser market will be supported by hospital modernization, with Germany’s Hospital Transformation Fund making up to €50 billion available from 2026 to 2035 for structural modernization of hospitals, while the country aims to develop a digitally supported healthcare ecosystem by 2030, supporting investment in advanced dermatological treatment technologies. The UK dermatology excimer laser market will be supported by increasing NHS investment in medical technology, with the government providing a £2.3 billion real-terms increase in annual NHS capital budgets through 2029-30 and up to £10 billion for technology and digital transformation by 2028-29, strengthening capacity for adoption of advanced medical devices and treatment technologies.
The France dermatology excimer laser market will be supported by healthcare innovation and hospital investment, with France’s Ségur de la santé providing €19 billion in investment support through 2030, including €15.5 billion for healthcare establishments, while France 2030 continues supporting new medical devices and healthcare innovations, strengthening opportunities for advanced dermatological equipment.
The dermatology excimer laser market is moderately fragmented, with specialized dermatology laser manufacturers, medical-device companies, phototherapy equipment providers, aesthetic laser manufacturers, and regional medical-technology suppliers competing across clinical and dermatological applications. Leading players such as Strata Skin Sciences, Inc., Alma Lasers, Lumenis Ltd., The Daavlin Company, and Fotona d.o.o. collectively account for approximately 40% of the global dermatology excimer laser market share.
Established players compete primarily on clinical efficacy, treatment precision, product portfolios, distribution networks, and after-sales support, while emerging and regional players in the dermatology excimer laser market ecosystem compete through compact and portable systems, simplified workflows, localized distribution, and faster product development. Competition is also influenced by treatment versatility, ease of use, reimbursement considerations, and business models such as equipment sales and recurring per-procedure arrangements.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Germany Surgical Equipment Market Size, Share and Forecast to 2034
Europe Surgical Equipment Market Size, Top Share and Forecast to 2034
Plasmapheresis Machines Market Size, Share, Growth, Analysis, 2034
Facial Cleansing Devices Market Size, Share, Growth, Analysis, 2034
Wearable Fitness Trackers Market Size, Share, Growth, Analysis, 2034
Bariatric Surgery Devices Market Size, Share, Growth, 2034
We are featured on:
sales@straitsresearch.com